Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal Tumors
NCT05751837Phase 1Completed
- Start
- Mar 2023
- Primary completion
- May 2024
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lipopolysaccharide endotoxin in Abdominal cancer. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 30 days. Started Mar 2023; status: completed.
02
Drugs
lipopolysaccharide endotoxin
03
Conditions
Abdominal cancer
Beyond the preview
Go deeper on NCT05751837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751837.